ABCL Company Profile and Key Details

AbCellera Biologics Inc. has 305.38 million shares outstanding. The public float is 205.09 million shares, elevated short interest at 20.00% of float. This equals 47.12 million shares. The short ratio is 4.99 days. Institutional investors hold 48.87% of the float. Insiders own 22.92%. Thermopylae Holdings Ltd. holds 56.13 million shares, THIEL PETER has 10.18 million shares and Lecault Veronique has 2.04 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Short-term trend indicators are bullishly aligned (SMA20 10.72%, SMA50 -1.07%, SMA200 -9.87%). The stock’s 14-day RSI is 54.9 (neutral), while the ATR of 0.26 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -44.9% below its high and over 89.89% above its low. Average 10-day trading volume of 9.09 million shares is slightly above the 3-month average of 6.95 million, indicating heightened recent market interest.

Wall Street analysts project EPS growth of -16.76% annually over the next five years. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at -$0.16. Next year's EPS is expected at -$13.97. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 2 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $11.00 to $4.00. The high target offers 49.05% upside. The low target suggests -45.8% downside. The mean target is $7.33. This offers -0.68% upside. AbCellera Biologics Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 11, 2026, missed forecasts by -36.36%. The prior quarter beat by -83.33%. Over the last six quarters, Apple has recorded several small beats. These include -26.67% in February 27, 2025.

AbCellera Biologics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$4.44. This means the shares are trading below this model’s fair value.

AbCellera Biologics Inc. (NASDAQ:ABCL) closed at $7.38 USD, gaining $0.72 (10.81%) from the previous close of $6.66. The stock is currently trading near its 52-week high $2.75 and $7.40. With a market capitalization of about $2.25 billion, AbCellera Biologics Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.20). Key stats such as the average daily volume over the past year has been around 7.17 million shares, trading with heavier-than-usual volume. Headquartered in Vancouver, BC, AbCellera Biologics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Carl Hansen, the company employs approximately 596 people and listed since December 11, 2020. AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies.

AbCellera Biologics Inc. trades at a P/E ratio of -14.43, slightly below the S&P 500 average, with a price-to-sales ratio of 26.7 and a price-to-book ratio of 2.24 suggesting the stock is closer to book value. The P/FCF stands at -11.18, also below market averages.

AbCellera Biologics Inc. (NASDAQ:ABCL) shares are up 21.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows AbCellera Biologics Inc. trading at a premium to the broader market with a P/E of -14.43. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $16.79, suggesting 127.51% upside. Our AI forecast model points to short-term strength (0.14% over two weeks), a medium-term rise (140.79% over three months), and a longer-term gain (242.68% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that AbCellera Biologics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.14%, with price expected at $7.39 by July 10, 2026, within a range of $6.80 to $7.97 3-Month Outlook: Projected rise of 140.79%, reaching $17.77 by September 24, 2026, with a range of $17.65 to $17.90. 1-Year Outlook: Projected gain of 242.68%, with price at $25.29 by June 25, 2027, within a range of $14.47 to $37.64.